Loading clinical trials...
Loading clinical trials...
Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial
Conditions
Interventions
Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed
Group 2: control group with enoxaparin 40mg/d
Locations
36
Brazil
Hospital Maternidade São Vicente de Paulo
Barbalha, Ceará, Brazil
Centro de Ensino e Aperfeiçoamento em Pesquisa - CEAP
Serra, Espírito Santo, Brazil
Centro de Estudos Clínicos do Hospital Cárdio Pulmonar
Salvador, Estado de Bahia, Brazil
Instituto de Ensino e Pesquisa do Hospital da Bahia
Salvador, Estado de Bahia, Brazil
Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel
Salvador, Estado de Bahia, Brazil
Centro de Pesquisas Cardiológicas de Goiânia do Hospital das Clínicas (UFG)
Goiânia, Goiás, Brazil
Start Date
June 21, 2020
Primary Completion Date
March 26, 2021
Completion Date
May 30, 2021
Last Updated
June 10, 2021
NCT06631287
NCT04885504
NCT04510025
NCT04326426
NCT05655351
NCT04610515
Lead Sponsor
Brazilian Clinical Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions